In a press release on Thursday, the agency said that after considering, in collaboration with external experts, the continued use of the heavily-scrutinized Covid-19 jab, that it would no longer recommend its use. It said more evidence has emerged to suggest there is a link between the jab and very rare cases of potentially fatal blood clots.
“Based on this knowledge, we have arrived at a recommendation that the AstraZeneca vaccine be removed from the coronavirus vaccination program in Norway,” Geir Bukholm, director of infection control at the National Institute of Public Health, said in the statement.
The institute noted that Norway has made great strides in vaccinating its elderly and those most at risk of Covid. Therefore, those who are yet to be vaccinated are younger and less at risk from the virus – but are also potentially more prone to thrombotic events linked to the AstraZeneca vaccine.